IN8bio Inc.

NASDAQ: INAB
Share price (12/20/24): $0.25
Market cap (12/20/24): $18.0 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/24 Q3

ended 06/30/24 Q2

ended 03/31/24 Q1

ended 12/31/23 FY 2023

ended 09/30/23 Q3

Prospectuses and Registrations Filter

Prospectus supplement

Shelf registration

Exempt offering of securities

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

BIOS Fund III NT, LP, BIOS Fund III QP, LP, BIOS Fund III, LP, Cavu Management, LP, Cavu Advisors, LLC, BP Directors, LP, Bios Equity Partners II, LP, Bios Equity Partners, LP, Kreis Leslie W., BIOS Equity Partners III, LP

BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, Fletcher Aaron G.L., BIOS Advisors GP, LLC, BIOS Capital Management, LP, Bios Clinical Opportunity Fund, LP, Bios Equity COF, LP

BIOS Fund II, LP

Fairbairn Emily

News Filter

Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements or Exhibits

Change in Directors, Officers or Compensation

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Scanned paper annual report submission

Notice of effectiveness